

HemoShear to be Featured at International Metabolic Conference

HemoShear is a Platinum Sponsor of the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held this week in Sydney Australia and online around the globe. ICIEM convenes more than 2,000 international scientists and clinicians from regional societies in inborn errors of metabolism every four years.

HemoShear is sponsoring a symposium during ICIEM titled "Introducing HST5040: A Systemic Small Molecule Approach for Methylmalonic and Propionic Acidemias." This session features Carlo Dionisi-Vici, MD, Head of Metabolic Diseases at the Ospedale Pediatrico Bambino Gesù in Italy, along with metabolic geneticist Kim Chapman, MD, PhD of Children's National Hospital and HemoShear Acting Chief Medical Officer Gerry Cox, MD, PhD. This virtual event will review the need for new treatments to improve outcomes in MMA and PA and the HST5040 clinical development program.



Brian Wamhoff describes our drug development for rare diseases in this short [video](#)

HemoShear's significant presence at the conference will also include a virtual booth for hosting online meetings and distributing materials. A brief video about the company will be played before a plenary session. You can watch it [here](#).

The company's research is being featured in two posters. Gerry Cox will present a poster on our HERO phase 2 trial design. Boston Children's Hospital psychiatrist Susan Waisbren, PhD, will share a poster on results of the Insight study to assess neuropsychological tests for methylmalonic acidemia (MMA) and propionic acidemia (PA).

"HemoShear is looking to expand our HST5040 clinical program into other parts of the world, and ICIEM presents a wonderful opportunity for us to introduce our company and HST5040 to key stakeholders," said Vice President of Communications Susan Klees. "We are excited to join other established metabolic disease companies in engaging with leaders in the clinical community globally."